drugset / Trial / NCT05814107
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
Phase 1
Completed
94 enrolled
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. · collabHoffmann-La Roche · collab
RandomizedSequentialDouble-blindTreatment
Summary
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
Timeline
- Start
- 2023-05-09
- Primary completion
- 2025-11-07
- Completion
- 2025-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RO7795081 | Unknown | — | — |